Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 13/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | EIF4E | P06730 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18177384 | 0.88 | ATR (0.56) | ATRNPC1TSHRRAB9A | |
| SCHEMBL16420503 | 0.87 | ATR (0.58) | ATR | |
| SCHEMBL13137845 | 0.85 | ATR (0.74) | ATR | |
| SCHEMBL17826101 | 0.85 | ATR (0.74) | ATR | |
| SCHEMBL16420457 | 0.83 | ATR (0.74) | ATRNPC1TSHRRAB9AMKNK1 | |
| SCHEMBL16420510 | 0.82 | ATR (0.63) | ATRNPC1RAB9AEIF4EKCNH2 | |
| SCHEMBL16420504 | 0.82 | NPC1 (0.60) | ATRNPC1TSHRRAB9AEIF4E | |
| SCHEMBL16420505 | 0.81 | ATR (0.71) | ATRNPC1TSHRRAB9AEIF4E | |
| SCHEMBL16420506 | 0.81 | ATR (0.77) | ATRNPC1TSHRRAB9AEIF4E | |
| SCHEMBL16489019 | 0.80 | ATR (0.74) | ATRTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701674-B2 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885NPC1 4192/4885TSHR 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.